Clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, Precision BioSciences along with its ARCUS genome editing platform, and Tiziana Life Sciences (NASDAQ:TLSA) announced on September 2, 2021, a specific license agreement for exploring Tiziana’sforalumab, a completely human anti-CD3 monoclonal antibody for inducing tolerance to improve the clinical outcome of CAR T cell therapy.
Alan List, M.D., Chief Medical Officer at Precision BioSciences, said that the firm is building an allogeneic CAR T platform with novel conditioning and editing strategies, like lymphodepleting agent. List added that the firm would explore the approach for improving the durability of clinical responses to its therapeutic platform.
KunwarShailubhai, Chief Executive Officer and Chief Scientific Officer of Tiziana Life Sciences, said that the firm is keen on offering Precision the chance to explore foralumab as a potential lymphodepletion strategy with their allogeneic CAR T programs. Shailubhai also said that relapse rates being high limits the broad utility of CAR T therapies and Precision’s approach of manufacturing has the potential to improve long-term success in cancer treatment.
The cluster of Differentiation 3, a receptor on effector T cells as well as an anti-CD3 antibody, can eliminate patient effector T cells. The process using ARCUS for knocking out the TRAC gene executes the CD3-depletion step.
